Michael P. Stansky's most recent trade in TriSalus Life Sciences Inc was a trade of 410,000 Common Stock done at an average price of $2.5 . Disclosure was reported to the exchange on May 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TriSalus Life Sciences Inc | Michael P. Stansky | Director | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 15 May 2026 | 410,000 | 1,240,722 | - | 2.5 | 1,025,000 | Common Stock |
| TriSalus Life Sciences Inc | Michael P. Stansky | Director | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 15 May 2026 | 200,000 | 399,698 | - | 2.5 | 500,000 | Common Stock |
| TriSalus Life Sciences Inc | Michael P. Stansky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 47,003 | 139,540 | - | - | Director Stock Option (right to buy) | |
| TriSalus Life Sciences Inc | Michael P. Stansky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 23,501 | 810,633 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Michael P. Stansky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 20,089 | 830,722 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Michael P. Stansky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 92,537 | 92,537 | - | - | Director Stock Option (right to buy) |